Investors Purchase High Volume of Call Options on Precigen (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) was the recipient of unusually large options trading on Thursday. Investors acquired 11,169 call options on the company. This is an increase of approximately 1,645% compared to the typical daily volume of 640 call options.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PGEN. Iridian Asset Management LLC CT increased its holdings in shares of Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after buying an additional 1,706,815 shares in the last quarter. LexAurum Advisors LLC increased its holdings in shares of Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after buying an additional 417,055 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Precigen by 4.8% during the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after buying an additional 149,829 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Precigen by 12.4% during the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after buying an additional 130,500 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after buying an additional 127,467 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Trading Up 16.4 %

NASDAQ PGEN traded up $0.19 on Thursday, hitting $1.32. 2,784,702 shares of the company’s stock were exchanged, compared to its average volume of 2,168,293. The stock has a 50-day moving average of $0.92 and a 200-day moving average of $1.06. The stock has a market cap of $385.12 million, a price-to-earnings ratio of -2.39 and a beta of 1.65. Precigen has a 52 week low of $0.65 and a 52 week high of $1.93.

Analyst Ratings Changes

Several research firms have recently commented on PGEN. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Precigen in a research report on Thursday. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.